Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. - Tsimberidou AM; Verschraegen C; Sigal D; Lenz HJ; Hochster H; Baysal MA; Chakraborty A; Lee I; Ristoski K; Xu D (The oncologist, 2026)